• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    11/14/24 4:46:46 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELEV alert in real time by email
    SC 13G/A 1 greatpoint-elev093024a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Elevation Oncology, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    28623U101

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     


     

    CUSIP No.  28623U101
     SCHEDULE 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Great Point Partners, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     

    0

    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%1
    12
    TYPE OF REPORTING PERSON
     
    IA/OO

    1 Based on the total of 59,106,809 shares of common stock outstanding as reported by the Issuer in its Form 10-Q filed with the SEC on August 6, 2024.

     


     

    CUSIP No.  28623U101
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Dr. Jeffrey R. Jay, M.D.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%1
    12
    TYPE OF REPORTING PERSON
     
    IN/HC

    1 Based on the total of 59,106,809 shares of common stock outstanding as reported by the Issuer in its Form 10-Q filed with the SEC on August 6, 2024.

     


     

    CUSIP No.  28623U101
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Ms. Lillian Nordahl
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%1
    12
    TYPE OF REPORTING PERSON
     
    IN/HC

    1 Based on the total of 59,106,809 shares of common stock outstanding as reported by the Issuer in its Form 10-Q filed with the SEC on August 6, 2024.

     


     

     

    CUSIP No. 28623U101
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Elevation Oncology, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    101 Federal Street, Suite 1900

    Boston, Massachusetts 02110

     

    Item 2.(a) Names of Persons Filing:

    Great Point Partners, LLC

    Dr. Jeffrey R. Jay, M.D.

    Ms. Lillian Nordahl

     

    The Reporting Persons have entered into a Joint Filing Agreement, dated November 14, 2024, a copy of which is filed with this SCHEDULE 13G/A as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

     

    Item 2.(b) Address of Principal Business Office:

    The address of the principal business office of each of the Reporting Persons is

     

    165 Mason Street, 3rd Floor

    Greenwich, CT 06830

     

    Item 2.(c) Citizenship:

    Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Ms. Lillian Nordahl is a citizen of the United States.

      

    Item 2.(d) Title of Class of Securities

    Common Stock, par value $0.0001 per share (the “Common Stock, par value $0.0001 per share”)

     

    Item 2.(e) CUSIP No.:

    28623U101

     

    CUSIP No.  28623U101
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 28623U101
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    1. Great Point Partners, LLC

    (a) Amount beneficially owned: 0 

    (b) Percent of class: 0%1 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or direct the vote: 0

    (ii) Shared power to vote or direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    2. Dr. Jeffrey R. Jay, M.D.

    (a) Amount beneficially owned: 0 

    (b) Percent of class: 0%1 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or direct the vote: 0

    (ii) Shared power to vote or direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    3. Ms. Lillian Nordahl

    (a) Amount beneficially owned: 0 

    (b) Percent of class: 0%1 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or direct the vote: 0

    (ii) Shared power to vote or direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    1 Based on the total of 59,106,809 shares of common stock outstanding as reported by the Issuer in its Form 10-Q filed with the SEC on August 6, 2024.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    See Item 4.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 28623U101
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Great Point Partners, LLC

           
      By:  /s/ Dr. Jeffrey R. Jay, M.D.
        Dr. Jeffrey R. Jay, M.D., as Senior Managing Member
           
     

    Dr. Jeffrey R. Jay, M.D.

           
      By:  /s/ Dr. Jeffrey R. Jay, M.D.
        Dr. Jeffrey R. Jay, M.D.
           
     

    Ms. Lillian Nordahl

           
      By:  /s/ Ms. Lillian Nordahl
        Ms. Lillian Nordahl
           

     

     
    CUSIP No. 28623U101
     SCHEDULE 13G/A
    Page 9 of 9 Pages

    Exhibit A

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned hereby agree as follows:

     

    (i) Each of them is individually eligible to use the SCHEDULE 13G/A to which this Exhibit is attached, and such SCHEDULE 13G/A is filed on behalf of each of them; and

     

    (ii) Each of them is responsible for the timely filing of such SCHEDULE 13G/A and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Great Point Partners, LLC

           
      By:  /s/ Dr. Jeffrey R. Jay, M.D.
        Dr. Jeffrey R. Jay, M.D., as Senior Managing Member
           
     

    Dr. Jeffrey R. Jay, M.D.

           
      By:  /s/ Dr. Jeffrey R. Jay, M.D.
        Dr. Jeffrey R. Jay, M.D.
           
     

    Ms. Lillian Nordahl

           
      By:  /s/ Ms. Lillian Nordahl
        Ms. Lillian Nordahl
    Get the next $ELEV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELEV

    DatePrice TargetRatingAnalyst
    3/24/2025$5.00 → $1.00Overweight → Equal-Weight
    Stephens
    3/21/2025$1.00Outperform → Market Perform
    Leerink Partners
    3/21/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/21/2025$0.70Overweight → Neutral
    Piper Sandler
    1/3/2025Outperform
    William Blair
    5/31/2024$10.00Overweight
    Piper Sandler
    5/14/2024$8.00Overweight
    Stephens
    3/1/2024$7.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $ELEV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Elevation Oncology downgraded by Stephens with a new price target

      Stephens downgraded Elevation Oncology from Overweight to Equal-Weight and set a new price target of $1.00 from $5.00 previously

      3/24/25 8:34:27 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Elevation Oncology from Outperform to Market Perform and set a new price target of $1.00

      3/21/25 8:03:34 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology downgraded by Citizens JMP

      Citizens JMP downgraded Elevation Oncology from Mkt Outperform to Mkt Perform

      3/21/25 8:03:24 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elevation Oncology Inc.

      SCHEDULE 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      5/15/25 4:27:14 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elevation Oncology Inc.

      SCHEDULE 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      5/15/25 4:15:23 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Elevation Oncology, Inc. (0001783032) (Filer)

      5/15/25 7:45:11 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

      -- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting -- -- Expects to file IND application for EO-1022 in 2026 -- -- Cash runway into 2H 2026 -- BOSTON, May 15, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2025, and provided recent business updates. "We recently presented preclinical proof-of-concept data for EO-1022, reaffirming its potential as a differentiated HER3 ADC, an

      5/15/25 7:30:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

      -- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors -- -- On-track to file IND application in 2026 -- BOSTON, April 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical proof-of-concept data for its novel HER3 antibody-drug conjugate (ADC), EO-1022. The data will be presented in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, b

      4/25/25 1:00:00 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

      -- Abstract accepted for late-breaking poster presentation – -- EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell lung cancers -- -- On-track to file an Investigational New Drug (IND) application in 2026 – BOSTON, March 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it will present preclinical data for its novel HER3 ADC, EO-1022, in a late-breaking poster presentation at the Amer

      3/25/25 4:30:00 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Furlong Tammy converted options into 2,643 shares and covered exercise/tax liability with 784 shares, increasing direct ownership by 23% to 10,075 units (SEC Form 4)

      4 - Elevation Oncology, Inc. (0001783032) (Issuer)

      5/19/25 4:15:05 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF EXECUTIVE OFFICER Ferra Joseph J Jr converted options into 6,250 shares and covered exercise/tax liability with 2,303 shares, increasing direct ownership by 3% to 137,152 units (SEC Form 4)

      4 - Elevation Oncology, Inc. (0001783032) (Issuer)

      5/19/25 4:10:05 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF EXECUTIVE OFFICER Ferra Joseph J Jr converted options into 12,562 shares and covered exercise/tax liability with 4,628 shares, increasing direct ownership by 6% to 133,205 units (SEC Form 4)

      4 - Elevation Oncology, Inc. (0001783032) (Issuer)

      3/18/25 4:15:13 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

      SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      11/14/24 7:50:19 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

      SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      11/14/24 7:05:59 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

      SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      11/14/24 6:45:37 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Financials

    Live finance-specific insights

    See more
    • Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements

      -- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Secured clinical supply agreements to evaluate EO-3021 in combination with ramucirumab and dostarlimab with Lilly and GSK, respectively; expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 2H 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30

      8/6/24 7:10:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

      -- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer ---- EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/hypoesthesia --  -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 ---- Expect to initiate dosing in combination portion of Phase 1 trial by year-end 2024 ---- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON, Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective ca

      8/6/24 7:00:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

      Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801)Expands pipeline to now include two clinical stage precision oncology candidates for patients with genomically defined solid tumors, including those with Claudin18.2 overexpressionCompany expects to initiate a Phase 1 clinical trial in the U.S. evaluating EO-3021 (SYSA1801) in 2023Management to host an investor conference call and webcast today at 5:00 p.m. ET NEW YORK, July 28, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, tod

      7/28/22 8:45:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Leadership Updates

    Live Leadership Updates

    See more
    • Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors

      BOSTON, March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of Directors. "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology. "Both are extremely experienced drug developers, who have contributed to the advancement and approval of multiple targeted therapies for the treatment of cancer. On behalf of the Board,

      3/4/24 7:30:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

      BOSTON, Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointment of Darcy Mootz, Ph.D., to its Board of Directors. Dr. Mootz is an experienced life sciences executive, who brings expertise across corporate strategy, corporate development, finance, and operations to Elevation Oncology's Board of Directors. "We are pleased to welcome Darcy to the Elevation Oncology board, as she is a uniquely qualified leader, who has experience crafting late-stage development str

      1/22/24 7:30:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer

      NEW YORK, July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announced today the appointment of Joseph Ferra, M.B.A., as its Chief Executive Officer. Mr. Ferra was previously Interim Chief Executive Officer and Chief Financial Officer. Mr. Ferra will also join the Elevation Oncology Board of Directors. In addition, the Company announced the appointment of Tammy Furlong, M.B.A., C.P.A., as Chief Financial Officer, promoted from her previous role as Vice President of Finance and Accounting

      7/13/23 8:00:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care